It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Investment will fund expansion to meet rising demand for CRDMO services
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Subscribe To Our Newsletter & Stay Updated
